the aid library

Filter

12053

Antibacterial agents in preclinical development: an open access database

World Health Organization WHO (2019) C_WHO

The pre-clinical pipeline shows more innovation and diversity, with 252 agents being developed to treat WHO priority pathogens. However, these products are in the very early stages of development and still need ... more

External Link

Effectiveness of one dose of oral cholera vaccine in response to an outbreak: a case-cohort study

Andrew S Azman, Lucy A Parker, John Rumunu, et al. The Lancet Global Health (2016) CC

Lancet Glob Health 2016; 4: e856–63. Open Access The article "Effectiveness of one dose of oral cholera vaccine in response to an outbreak: a ca ... more

Download

View PDF

Finding the Balance: Public Health and Social Measures in Zimbabwe

Partnership for Evidence-Based Response to COVID-19 (PERC) (2021) CC

This report describes findings from a telephone survey with 1,284 people conducted in February 2021. The survey examined how people respond to public health and social measures (PHSMs) ... more

Download

View PDF

Finding the Balance: Public Health and Social Measures in Mozambique

Partnership for Evidence-Based Response to COVID-19 (PERC) (2021) CC

This report describes findings from a telephone survey with 1,333 people conducted in February 2021. The survey examined how people respond to public health and social measures (PHSMs) ... more

Download

View PDF

Finding the Balance: Public Health and Social Measures in Cameroon

Partnership for Evidence-Based Response to COVID-19 (PERC) (2021) CC

This report describes findings from a telephone survey with 1,323 people conducted in February 2021. The survey examined how people respond to public health and social measures (PHSMs) ... more

Download

View PDF

Finding the Balance: Public Health and Social Measures in DRC

Partnership for Evidence-Based Response to COVID-19 (PERC) (2021) CC

This report describes findings from a telephone survey with 1,316 people conducted in February 2021. The survey examined how people respond to public health and social measures (PHSMs) ... more

Download

View PDF

Vienna Declaration: building forward better by transforming to new, clean, safe, healthy and inclusive mobility and transport

World Health Organization (WHO) (2022) C_WHO

The Vienna Declaration was signed at the end of the Fifth High-level Meeting on Transport, Health and Environment. The virtual meeting, hosted by the Federal Government of Austria, brought together 46 ministers and representatives of 56 countries in ... more

Download

View PDF

Finding the Balance: Public Health and Social Measures in Zambia

Partnership for Evidence-Based Response to COVID-19 (PERC) (2021) CC

This report describes findings from a telephone survey with 1,328 people conducted in February 2021. The survey examined how people respond to public health and social measures (PHSMs) ... more

Download

View PDF

Rapid Communication: Key changes to treatment of multidrug- and rifampicin-resistant tuberculosis (MDR/RR-TB)
recommended

World Health Organization WHO (2018) C_WHO

The first important change is a new priority ranking of the available medicines for MDR-TB treatment, based on a careful balance between expected benefits and harms. Treatment success for MDR-TB is currently low in many countries. This could be increased by improving ... more

External Link

Infrastructure, policy and regulatory interventions to increase physical activity to prevent cardiovascular diseases and diabetes: a systematic review

Durão, S.; Burns, J.; Schmidt, B. et al. BMC Public Health (2023) CC

Background Noncommunicable diseases are major contributors to morbidity and mortality worldwide. Modifying the risk factors for these conditions, such as physical inactivity, is thus essential. Addressing the context or circumstances in which physi ... cal activity occurs may promote physical activity at a population level. We assessed the effects of infrastructure, policy or regulatory interventions for increasing physical activity. Methods We searched PubMed, Embase and clinicaltrials.gov to identify randomised controlled trials (RCTs), controlled before-after (CBAs) studies, and interrupted time series (ITS) studies assessing population-level infrastructure or policy and regulatory interventions to increase physical activity. We were interested in the effects of these interventions on physical activity, body weight and related measures, blood pressure, and CVD and type 2 diabetes morbidity and mortality, and on other secondary outcomes. Screening and data extraction was done in duplicate, with risk of bias was using an adapted Cochrane risk of bias tool. Due to high levels of heterogeneity, we synthesised the evidence based on effect direction. Results We included 33 studies, mostly conducted in high-income countries. Of these, 13 assessed infrastructure changes to green or other spaces to promote physical activity and 18 infrastructure changes to promote active transport. The effects of identified interventions on physical activity, body weight and blood pressure varied across studies (very low certainty evidence); thus, we remain very uncertain about the effects of these interventions. Two studies assessed the effects of policy and regulatory interventions; one provided free access to physical activity facilities and showed that it may have beneficial effects on physical activity (low certainty evidence). The other provided free bus travel for youth, with intervention effects varying across studies (very low certainty evidence). Conclusions Evidence from 33 studies assessing infrastructure, policy and regulatory interventions for increasing physical activity showed varying results. The certainty of the evidence was mostly very low, due to study designs included and inconsistent findings between studies. Despite this drawback, the evidence indicates that providing access to physical activity facilities may be beneficial; however this finding is based on only one study. Implementation of these interventions requires full consideration of contextual factors, especially in low resource settings. more

Download

View PDF

Frequently Asked Questions (FAQs) about COVID-19 Candidate Vaccines and Access Mechanisms. Version 3, 6 January 2021

Pan American Health Organisation PAHO (2021) C_WHO

Will COVID-19 vaccines be safe? Will all the COVID-19 candidate vaccines be successful? What are the different phases a vaccine must go through to be approved? This document provides responses to th ... more

Download

View PDF

COVID-19: How to include marginalized and vulnerable people in risk communication and community engagement

Inter-Agency Standing Committee IASC; World Health Organization (WHO); UNICEF; et al. (2020) C1

Women, the elderly, adolescents, youth, and children, persons with disabilities, indigenous populations, refugees, migrants, and minorities experience the highest degree of socio-economic marginalization. Marginalized people become even more vulnerable in emergencies.1 This is due ... more

Download

View PDF

Alcohol and COVID-19: what you need to know (Arabic Version)

World Health Organization WHO; Regional Office for the Eastern Mediterreanan (2020) CC

This infographic provides important information on what to do and what not to do in regard to alcohol during the COVID-19 pandemic, including: avoi ... more

External Link

Stronger Together: Building Individual and Social Resilience to Cope with the Impacts of Natural Hazard Events

Pan American Health Organization (PAHO) and the Caribbean Development Bank (CDB) (2019) CC

Under the theme “Stronger Together”, the campaign aims to offer information and strategies to assist communities in the region in better coping with the psychological impact of adverse events be ... more

External Link

Keeping communities at the centre of efforts to eliminate lymphatic filariasis: learning from the past to reach a future free of lymphatic filariasis

Krentel, A.; Gyapong, M.; McFarland, D.A.; Ogundahunsi, O.; Titaley, C.R.; Addiss, D.G. Oxford Academic - International Health (2021) CC

Since the launch of the Global Programme to Eliminate Lymphatic Filariasis (GPELF) in 2000, more than 910 million people have received preventive chemotherapy for lymphatic filariasis (LF) and many thousands have received care for chronic manifestat ... more

External Link

Bringing high-impact, good-quality and low-cost eye care closer to home: a case study of Klinik Katarak-Kementerian Kesihatan Malaysia

World Health Organization WHO (2023) C_WHO

Health innovation is the creation and implementation of novel processes, products, programmes, policies or systems that lead to transformations or improvements in ... more

Download

View PDF

Improving the Quality of PrEP Implementation for Adolescent Girls and Young Women: An implementation brief to support programming in Eastern and Southern Africa

World Health Organization WHO, Regional Office of Africa; UNICEF (2021) C_WHO

Adolescent girls and young women (AGYW) remain disproportionately affected by HIV in Eastern and Southern Africa (ESA), with 26 per cent of new infections attributed to this population. AGYW face many personal, social and structural barriers ... more

Download

View PDF

EPI 1: Antiepileptic medications for management of acute convulsive seizures when no intravenous access is available

World Health Organization WHO (2015) C_WHO

[Updated 2015] Scoping Question: In adults with acute convulsive seizures in first-level care or in the community (when no IV access is available), which antiepileptic medications produce benefits and/or harm when compared ... more

External Link

Transforming APOC into a new regional entity for Oncho & LF elimination and support to other PC/NTD

World Health Organization World Health Organization WHO; African Programme for Onchocerciasis Control APOC (2013) C_WHO

In May the Sixty-sixth World Health Assembly adopted resolution WHA66.12 (1) on 17 neglected tropical diseases (NTDs). Among other measures, the resolution urges Member States to: • ensure count ... more

Rapid Communication: Key changes to treatment of multidrug- and rifampicin-resistant tuberculosis (MDR/RR-TB) recommended

Rapid Communication: Key changes to treatment of multidrug- and rifampicin-resistant tuberculosis (MDR/RR-TB)
recommended